Par to pay $100m to settle Salix patent suit
This article was originally published in Scrip
Executive Summary
Par Pharmaceutical will pay $100m to settle a patent infringement suit involving Salix Pharmaceuticals' oral proton-pump inhibitor Zegerid, an immediate-release form of omeprazole plus sodium bicarbonate indicated to treat heartburn and other symptoms that happen with gastroesophageal reflux disease.